Skip to content
AnalystLens

Medpace Holdings Annual Report, Year Ended Dec 31, 2023

Filing Date
Filed February 13, 2024
Period End
December 31, 2023
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’17Dec ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Material agreement8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 10-K filed February 13, 2024. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. reported a strong 2023 in its 10-K filed February 13, 2024.

Revenue, net rose $425.8 milliona, or 29.2%, to $1,885.8 million, up from $1,460.0 million in 2022. Income from operations reached $336.8 million, and net income was $282.8 million, compared with $245.4 million in 2022. Diluted EPS was $8.88, versus $7.28 a year earlier.

Growth was broad based, driven mainly by Metabolic, Oncology, and AVAI therapeutic areas. Backlog grew $473.4 millionb, or 20.2%, to $2,813.0 million at December 31, 2023. Net new business awards were $2,356.7 million, up from $1,829.5 million.

The company expects approximately $1,520.0 million to $1,540.0 millionc of backlog to convert to net revenue in 2024. The filing also notes that most customer contracts are terminable without cause on 30 days' notice, so backlog is not necessarily a meaningful predictor of future results. Cash and cash equivalents increased to $245.4 million from $28.3 million, and the company reported no outstanding indebtedness at year-end 2023.

Operating cash flow was $433.4 milliond. The company repurchased $144.0 million of common stock during 2023 and had $308.8 million remaining under its current repurchase authorization.

Risk factors highlight customer concentration (top ten customers at 29.5% of net revenue), fixed-fee contract exposure, and the influence of Chief Executive Officer and founder August J. Troendle, who controls approximately 20.8% of outstanding shares.

Key Highlights

  1. Revenue, net of $1,885.8 million, up 29.2% from $1,460.0 million in 2022
  2. Net income of $282.8 million and diluted EPS of $8.88, versus $245.4 million and $7.28 in 2022
  3. Backlog of $2,813.0 million at December 31, 2023, up 20.2%; net new business awards of $2,356.7 million
  4. Approximately $1,520.0 million to $1,540.0 million of backlog expected to convert to net revenue in 2024
  5. Cash and cash equivalents of $245.4 million, with no indebtedness outstanding at December 31, 2023
  6. Operating cash flow of $433.4 million and $144.0 million in share repurchases during 2023
  7. Top ten customers represent approximately 29.5% of net revenue; no single customer exceeded 10%

Financial Statements

FY2023 against FY2022

Line itemFY2023FY2022Change
Revenue$1.89B$1.46B+29.2%
SG&A Expenses$161.35M$131.40M+22.8%
Operating Expenses$1.55B$1.18B+31.1%
Operating Income$336.82M$278.70M+20.9%
Net Income$282.81M$245.37M+15.3%
EPS (Basic)$9.20$7.57+21.5%
EPS (Diluted)$8.88$7.28+22.0%
Shares Outstanding (Basic)30.72M32.39M−5.1%
Shares Outstanding (Diluted)31.84M33.67M−5.4%

Frequently Asked Questions

  1. How much did Medpace's revenue and profit grow in 2023?

    Revenue, net increased by $425.8 million, or 29.2%, to $1,885.8 million. Income from operations rose to $336.8 million from $278.7 million, and net income increased to $282.8 million from $245.4 million.

  2. What does the backlog figure indicate about future revenue?

    Backlog increased 20.2% to $2,813.0 million, and about $1,520.0 million to $1,540.0 million is expected to convert to net revenue in 2024. The filing cautions that most contracts can be terminated without cause on 30 days' notice, so backlog may not be a meaningful predictor of future results.

  3. How strong is Medpace's balance sheet and cash position?

    Cash and cash equivalents rose to $245.4 million from $28.3 million at year-end 2022. The company had no outstanding indebtedness as of December 31, 2023, and $150.0 million was available under its Credit Facility.

  4. What are the main concentration and control risks for shareholders?

    The top ten customers accounted for approximately 29.5% of net revenue, and small and mid-sized biopharmaceutical companies made up 78% and 18% of net revenue, respectively. CEO and founder August J. Troendle controls approximately 20.8% of outstanding shares and can exert significant influence over corporate matters.

  5. How is Medpace returning capital to shareholders?

    The company does not pay dividends and instead repurchased $144.0 million of common stock in 2023 under its new program. It had $308.8 million of remaining authorization at December 31, 2023.